Alembic Pharmaceuticals has raised funds aggregating to Rs 350 crore via private placement. The NCD Committee of the company at their meeting held on December 14, 2018 has allotted 1,500 9% Rated Unsecured Listed Redeemable Non-Convertible Debentures (NCDs) of Rs 10 lakh per NCD aggregating to Rs 150 crore under Tranche I, and 2,000 9% Rated Unsecured Listed Redeemable NCDs of Rs 10 lakh per NCD aggregating to Rs 200 crore under Tranche II. The said NCDs shall be listed on the National Stock Exchange of India.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1834.40 |
| Dr. Reddys Lab | 1306.80 |
| Cipla | 1362.85 |
| Zydus Lifesciences | 940.10 |
| Lupin | 2459.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: